Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBig Technologies Regulatory News (BIG)

Share Price Information for Big Technologies (BIG)

Share Price is delayed by 15 minutes
Get Live Data
102.00    0.00 (0.00%)
Bid:
102.00
Ask:
104.00
Spread: 2.00 (1.961%)
Market Cap: £298.07m
BIG Live PriceLast checked at - London Stock Exchange

Intraday Big Technologies Share Chart

Trading Update

8 Dec 2025 07:00

RNS Number : 5389K
Big Technologies PLC
08 December 2025
 

Big Technologies plc

("Big Technologies" or "the Company", together with its subsidiaries the "Group")

Trading Update

Rickmansworth - 8 December 2025 - Big Technologies plc (AIM: BIG), a leading provider of electronic monitoring solutions provides the following update to 8th December 2025.

· New Business Wins in Lithuania, Latvia, and Pierce County (Washington state), subject to final contract. New contract signed in Prince Edward Island, Canada. All of the contracts and awards are expected to generate ARR to the group over the course of 2026 as they come online and reduce customer concentration. The largest award, Lithuania, will deliver an initial ARR of £0.6m expected to materialise in 2026, with the opportunity to grow to a total contract value of up to c. €6m over a three- year term.

 

· Partnership agreed with US based Recovery Monitoring Solutions ('RMS'). Buddi has signed a strategic partnership with RMS to provide state-of-the-art alcohol monitoring and GPS products to their clients. RMS has a 32-year history of delivering innovative solutions to their customers, and we are pleased to be working with them to increase their product portfolio, and further expand Buddi's reach in the USA.

 

· Product Certification: The Group has recently developed a new product to measure breath alcohol, called 'AlcoBreath' which has recently received FCC ("Federal Communications Commission") approval in the USA. The unit combines breath alcohol detection, real time GPS tracking, and facial recognition in a robust, compact handheld device. The Group believes there is a significant market, particularly in the USA, for compliance-based alcohol monitoring.

The Group expects to release its full year trading update at the end of January 2026 and new contract wins underpin confidence in the Group's trading in line with market expectations.

Ian Johnson, Big Technologies CEO, said:

"We are continuing to progress our transformation programme, strengthening our organisation and delivering profitable growth. We are delighted with the recent awards and validation of the competitiveness of the Buddi proposition to customers globally.

The Group remains well-positioned with the financial flexibility underpinned by a strong balance sheet and operational cashflow to continue to invest in product and market development. The electronic monitoring market continues to experience significant tailwinds. The Company has a clear growth strategy and market leading products, which places the Group in a strong position to compete for new business globally.

The Group has seen rapid progress in the second half of 2025, underpinned by investments made to strengthen the Group organisationally and operationally. The performance across the Group, driven by management actions and strategic initiatives has built confidence in meeting our full year guidance for revenue and adjusted EBITDA1."

 

1The company has compiled forecasts from five analysts with current market forecasts for 2025 revenue to be in the range of £48.5m to £49.5m, with a consensus of £49.1m, and for adjusted EBITDA to be in the range of £23.7m to £24.5m, with a consensus of £24.1m.

-Ends-

 

Enquiries

Big Technologies plc

+44 (0) 192 360 1910

Ian Johnson (Chief Executive Officer)

Mike Johns (Chief Financial Officer)

Zeus (Nominated Adviser and Joint Broker)

 +44 (0) 203 829 5000

Dan Bate / Kieran Russell (Investment Banking)

Benjamin Robertson (Equity Capital Markets)

Singer Capital Markets (Joint Broker)

 +44 (0) 207 496 3000

James Moat / James Todd (Investment Banking)

 

About

Big Technologies is a market leader in the remote personal monitoring industry, operating under the trusted 'Buddi' brand. The Company delivers innovative, high-quality solutions that combine advanced hardware and software to support the monitoring of individuals in the criminal justice sector.

Through its integrated technology platform, Big Technologies offers state-of-the-art Electronic Monitoring solutions on a subscription-based, SaaS-like model. This platform is highly flexible and scalable, enabling tailored deployments across diverse use cases and geographies.

The Company's core technologies are designed to meet the evolving needs of governments and agencies, ensuring safety, compliance, and peace of mind through reliable, real-time monitoring.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVAFELEIIE
Date   Source Headline
4th Dec 202312:40 pmRNSEBT Share Purchase
20th Nov 202310:58 amRNSEBT Share Purchase
10th Nov 20239:08 amRNSDirector/PDMR Shareholding
8th Nov 20231:48 pmRNSEBT Share Purchase
1st Nov 20231:42 pmRNSEBT Share Purchase
25th Oct 202310:22 amRNSDirector/PDMR Shareholding
24th Oct 20234:57 pmRNSDirector/PDMR Shareholding - Replacement
24th Oct 202312:23 pmRNSDirector/PDMR Shareholding
24th Oct 202311:55 amRNSDirector/PDMR Shareholding - Replacement
23rd Oct 20235:05 pmRNSDirector/PDMR Shareholding
23rd Oct 20235:03 pmRNSEBT Share Purchase
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20239:05 amRNSIncrease in Share Capital
11th Oct 20231:40 pmRNSEBT Share Purchase
10th Oct 202311:40 amRNSEBT Share Purchase
3rd Oct 20237:00 amRNSEBT Share Purchase
28th Sep 20237:00 amRNSEBT Share Purchase
21st Sep 20237:00 amRNSEstablishment of an Employee Benefit Trust
19th Sep 20237:00 amRNSHalf-year Report
4th Aug 20238:57 amRNSStatement re legal claim
18th Jul 20237:00 amRNSIncrease in share capital and director dealing
7th Jun 20237:00 amRNSIncrease in share capital
23rd May 20231:43 pmRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
17th May 20232:10 pmRNSIncrease in Share Capital
26th Apr 20231:40 pmRNS2022 Annual Report and Notice of AGM
21st Apr 202310:27 amRNSDirector/PDMR Shareholding
5th Apr 20231:04 pmRNSDirector/PDMR Shareholding
4th Apr 202312:27 pmRNSDirector/PDMR Shareholding
31st Mar 202312:12 pmRNSIncrease in Share Capital
29th Mar 20237:00 amRNS2022 Preliminary audited results
23rd Mar 20231:01 pmRNSHolding(s) in Company
20th Jan 20237:00 amRNSTrading Statement
8th Dec 202212:38 pmRNSIncrease in share capital
18th Oct 20227:00 amRNSIncrease in share capital
20th Sep 20227:00 amRNSDirector/PDMR Shareholding
20th Sep 20227:00 amRNSDirector/PDMR Shareholding
15th Sep 20227:00 amRNSHalf-year Report
14th Sep 20224:48 pmRNSHolding(s) in Company
13th Sep 20224:36 pmRNSPrice Monitoring Extension
6th Sep 20224:40 pmRNSSecond Price Monitoring Extn
6th Sep 20224:35 pmRNSPrice Monitoring Extension
26th Aug 20224:40 pmRNSSecond Price Monitoring Extn
26th Aug 20224:35 pmRNSPrice Monitoring Extension
1st Aug 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20222:03 pmRNSDirector/PDMR Shareholding
1st Aug 202211:50 amRNSIncrease in share capital
25th Jul 20227:00 amRNSDirector/PDMR Shareholding
22nd Jun 202212:19 pmRNSIncrease in share capital
16th Jun 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.